Cargando…
Moxifloxacin in situ gelling microparticles–bioadhesive delivery system
Antibiotic use for ocular treatments has been largely limited by poor local bioavailability with conventional eyedrops formulations. Here, we developed a controlled delivery system composed of moxifloxacin-loaded poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulated in a chondroitin sulfa...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167180/ https://www.ncbi.nlm.nih.gov/pubmed/25755996 http://dx.doi.org/10.1016/j.rinphs.2012.09.002 |
_version_ | 1782335379833094144 |
---|---|
author | Guo, Qiongyu Aly, Ahmed Schein, Oliver Trexler, Morgana M. Elisseeff, Jennifer H. |
author_facet | Guo, Qiongyu Aly, Ahmed Schein, Oliver Trexler, Morgana M. Elisseeff, Jennifer H. |
author_sort | Guo, Qiongyu |
collection | PubMed |
description | Antibiotic use for ocular treatments has been largely limited by poor local bioavailability with conventional eyedrops formulations. Here, we developed a controlled delivery system composed of moxifloxacin-loaded poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulated in a chondroitin sulfate-based, two-component bioadhesive hydrogel. Using a simple and fast electrohydrodynamic spray drying (electrospraying) technique, surfactant-free moxifloxacin-loaded microparticles were fabricated with diameters on the order of 1 μm. A mixed solvent system of methanol/dichloromethane (MeOH/DCM) was employed to prepare the microparticles for the electrospraying processing. Extended release of moxifloxacin using a series of MeOH/DCM mixed solvents was accomplished over 10 days with release concentrations higher than the minimum inhibitory concentration (MIC). In contrast, moxifloxacin loaded directly in hydrogels was released rapidly within 24 h. We observed a decrease of the drug release rate from the microparticles when using an increased percentage of methanol in the mixed solvent from 10% to 30% (v/v), which can be explained by the mixed solvent system providing a driving force to form a gradient of the drug concentrations inside the microparticles. In addition, the delivery system developed in this study, which incorporates a bioadhesive to localize drug release by in situ gelling, may potentially integrate antibiotic prophylaxis and wound healing in the eye. |
format | Online Article Text |
id | pubmed-4167180 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-41671802015-03-09 Moxifloxacin in situ gelling microparticles–bioadhesive delivery system Guo, Qiongyu Aly, Ahmed Schein, Oliver Trexler, Morgana M. Elisseeff, Jennifer H. Results Pharma Sci Article Antibiotic use for ocular treatments has been largely limited by poor local bioavailability with conventional eyedrops formulations. Here, we developed a controlled delivery system composed of moxifloxacin-loaded poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulated in a chondroitin sulfate-based, two-component bioadhesive hydrogel. Using a simple and fast electrohydrodynamic spray drying (electrospraying) technique, surfactant-free moxifloxacin-loaded microparticles were fabricated with diameters on the order of 1 μm. A mixed solvent system of methanol/dichloromethane (MeOH/DCM) was employed to prepare the microparticles for the electrospraying processing. Extended release of moxifloxacin using a series of MeOH/DCM mixed solvents was accomplished over 10 days with release concentrations higher than the minimum inhibitory concentration (MIC). In contrast, moxifloxacin loaded directly in hydrogels was released rapidly within 24 h. We observed a decrease of the drug release rate from the microparticles when using an increased percentage of methanol in the mixed solvent from 10% to 30% (v/v), which can be explained by the mixed solvent system providing a driving force to form a gradient of the drug concentrations inside the microparticles. In addition, the delivery system developed in this study, which incorporates a bioadhesive to localize drug release by in situ gelling, may potentially integrate antibiotic prophylaxis and wound healing in the eye. Elsevier 2012-09-25 /pmc/articles/PMC4167180/ /pubmed/25755996 http://dx.doi.org/10.1016/j.rinphs.2012.09.002 Text en © 2012 Elsevier B.V. All rights reserved. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). |
spellingShingle | Article Guo, Qiongyu Aly, Ahmed Schein, Oliver Trexler, Morgana M. Elisseeff, Jennifer H. Moxifloxacin in situ gelling microparticles–bioadhesive delivery system |
title | Moxifloxacin in situ gelling microparticles–bioadhesive delivery system |
title_full | Moxifloxacin in situ gelling microparticles–bioadhesive delivery system |
title_fullStr | Moxifloxacin in situ gelling microparticles–bioadhesive delivery system |
title_full_unstemmed | Moxifloxacin in situ gelling microparticles–bioadhesive delivery system |
title_short | Moxifloxacin in situ gelling microparticles–bioadhesive delivery system |
title_sort | moxifloxacin in situ gelling microparticles–bioadhesive delivery system |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167180/ https://www.ncbi.nlm.nih.gov/pubmed/25755996 http://dx.doi.org/10.1016/j.rinphs.2012.09.002 |
work_keys_str_mv | AT guoqiongyu moxifloxacininsitugellingmicroparticlesbioadhesivedeliverysystem AT alyahmed moxifloxacininsitugellingmicroparticlesbioadhesivedeliverysystem AT scheinoliver moxifloxacininsitugellingmicroparticlesbioadhesivedeliverysystem AT trexlermorganam moxifloxacininsitugellingmicroparticlesbioadhesivedeliverysystem AT elisseeffjenniferh moxifloxacininsitugellingmicroparticlesbioadhesivedeliverysystem |